Comparison between FOLFIRINOX and gemcitabine plus nab-paclitaxel including sequential treatment for metastatic pancreatic cancer: a propensity score matching approach

BACKGROUND: FOLFIRINOX (FFX) and Gemcitabine plus nab-paclitaxel (GnP) have been recommended as the first-line chemotherapy for metastatic pancreatic cancer (mPC). However, the evidence is lacking comparing not only two regimens, but also sequential treatment (FFX–GnP vs. GnP–FFX). METHODS: Data of...

Descripción completa

Detalles Bibliográficos
Autores principales: Chun, Jung Won, Lee, Sang Hyub, Kim, Joo Seong, Park, Namyoung, Huh, Gunn, Cho, In Rae, Paik, Woo Hyun, Ryu, Ji Kon, Kim, Yong-Tae
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8114681/
https://www.ncbi.nlm.nih.gov/pubmed/33975561
http://dx.doi.org/10.1186/s12885-021-08277-7

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8114681/
https://www.ncbi.nlm.nih.gov/pubmed/33975561
http://dx.doi.org/10.1186/s12885-021-08277-7

Ejemplares similares